Study registration: *
Publication Layan M, medRxiv, 2021
Dates: 2020-12-31 to 2021-04-26
Funding: Mixed (Sheba Medical Center. SC acknowledges financial support from the Investissement d’Avenir program, the Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases program (grant ANR-10-LABX-62-IBEID), HAS, the INCEPTION project (PIA/ANR-16-CONV-0005), the European Union’s Horizon 2020 research and innovation program under grant 101003589 (RECOVER) and 874735 (VEO), AXA and Groupama)
Conflict of interest: no COI (None declared)

Methods

Study design:Cohort
Description of participants: Household members close contact of an HCW index case
Inclusion criteria:
  • "the HCW who were SARS-CoV-2 positive or reported a positive household member were contacted at least ten days after detection and were offered to join the study. Those who agreed and gave their consent, answered a telephone interview."

Exclusion criteria:
  • Those who did not agree and did not give their consent.

Follow-up duration (months): 4
Vaccines:
  • 1 or 2 doses of BNT162b2
Variant description :
Variant name: Alpha
Evidence: Indirect evidence (prevalence of variant in the population: 90)
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated: Uncl, Data and code will be published online upon publication
Data accessibility: Data and code will be published online upon publication
General comment Concerns regarding residual confounding (age, sex, comorbidities, socioeconomic status and ethnicity were not considered) and about information used to classify the intervention groups recorded retrospectively by self report.